Skip to content

Study · In vitro (cells) · 2012

1 result

Thymosin α1 and cancer: action on immune effector and tumor target cells.

Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P, Sinibaldi-Vallebona P

Annals of the New York Academy of Sciences1 Oct 2012Cited by 62 (Europe PMC)

PMID23045967 (opens in a new tab)DOI10.1111/j.1749-6632.2012.06697.x (opens in a new tab)PepBankPUB-23045967
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In experimental and human tumor cell lines, thymosin alpha‑1 increased the expression of tumor antigens.

    In plain wordsIn cells, thymosin alpha‑1 raised the amount of tumor antigens on tumor cell lines.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTumor antigen expression
    Study

    n: not reported in source

    Experimental and human tumor cell lines
    Outcome group
    Immune response · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the present paper, we describe preliminary data indicating that Tα1 is also capable of increasing the expression of tumor antigens in both experimental and human tumor cell lines.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 2 ongoing · 1 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT07103395

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

Sun Yat-sen Universityn = 561 Jan 2026 to est. 30 Dec 2029

Lung Cancer (NSCLC)

Trial pageClinicalTrials.govUpdated 14 Jan 2026
Not yet recruitingPhase 2NCT07103408

A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer

Sun Yat-sen Universityn = 56est. 1 Oct 2025 to est. 30 Sept 2029

Small-Cell Lung Cancer (SCLC)

Trial pageClinicalTrials.govUpdated 5 Aug 2025
CompletedPhase 2NCT06139419

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Sun Yat-sen Universityn = 11425 Jul 2023 to 30 Jun 2026

Non-small Cell Lung Cancer

Trial pageClinicalTrials.govUpdated 3 Aug 2026
RecruitingPhase 2NCT07644897

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

Sun Yat-sen Universityn = 5530 May 2023 to est. 30 Sept 2027

Melanoma · Immune-related Adverse Event · Immune Checkpoint Inhibitor

Trial pageClinicalTrials.govUpdated 12 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.